DCAF16 Knockout HeLa Cell Line
Cat.No.:
EDC90417
Species:
Human
Cell Name:
HeLa
Gene:
DCAF16
Gene ID:
54876
Size:
1×10⁶cells
DCAF16 Knockout Cell Line (Hela) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC90417 |
|---|---|
| Product Name | DCAF16 Knockout Hela Cell Line |
| Cell Line | Hela |
| Cellosaurus ID | CVCL_0030 |
| Cell Line Synonyms | HELA, Hela, He La, He-La, HeLa-CCL2, Henrietta Lacks cells, Helacyton gartleri |
| Gene | DCAF16 |
| NCBI Gene ID | |
| Gene Synonyms | C4orf30 |
| Summary |
Predicted to be involved in protein ubiquitination. Part of Cul4-RING E3 ubiquitin ligase complex. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Cervical Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5, 2days |
| Complete Culture Medium | MEM + 10% FBS |
| Freezing Medium | 70%Complete culture medium+ 20% FBS+ 10% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HeLa | STR Info (Cell bank) Cell Line: HeLa | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1PO | 9 | 10 | 9 | 10 |
| D1S1656 | 12 | 15 | 12 | 15 |
| D2S1338 | 17 | 17 | ||
| D3S1358 | 15 | 18 | 15 | 18 |
| D5S818 | 11 | 12 | 11 | 12 |
| D6S1043 | 18 | 18 | ||
| D7S820 | 8 | 12 | 8 | 12 |
| D8S1179 | 12 | 13 | 12 | 13 |
| D12S391 | 20 | 25 | 20 | 25 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 10 | 9 | 10 |
| D18S51 | 16 | 16 | ||
| D19S433 | 13 | 14 | 13 | 14 |
| D21S11 | 27 | 28 | 27 | 28 |
| FGA | 18 | 21 | 18 | 21 |
| Penta D | 8 | 15 | 8 | 15 |
| Penta E | 7 | 17 | 7 | 17 |
| TPOX | 8 | 12 | 8 | 12 |
| VWA | 16 | 18 | 16 | 18 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying DCAF16 function, DCAF16 Knockout HeLa Cell Line or DCAF16 overexpression HeLa Cell Line?
The choice depends on whether you are studying DCAF16 (DDB1- and CUL4-associated factor 16)'s role as a CRL4 substrate receptor or modeling its emerging applications in covalent molecular glue degraders. The Knockout line is the standard tool for asking whether DCAF16 is required for these processes — DCAF16 is one of the ~70 DCAF (DDB1- and CUL4-associated factor) substrate receptors that, together with DDB1 and CUL4A/4B, form CRL4 E3 ubiquitin ligase complexes; DCAF16 contains a key surface cysteine (C58, C107, or other) recently characterized as a target for covalent molecular glue degraders. Overexpression is useful for studying DCAF16 in heterologous expression contexts.
For targeted protein degradation research, the EDITGENE DCAF16 Knockout in HeLa is uniquely valuable — DCAF16 has emerged as one of the most promising targets for covalent molecular glue degrader (CovGD) development, with recent studies (Henning et al. 2022; Pluciński et al. 2023) showing that small molecules can covalently engage DCAF16 cysteines to recruit neo-substrates for degradation. Rescue with wild-type or cysteine-mutant (C58A, C107A) DCAF16 enables systematic characterization of covalent molecular glue mechanism. The knockout is a critical specificity tool for emerging DCAF16-recruiting covalent degraders and broader exploration of cysteine-reactive molecular glue platforms — DCAF16 is at the forefront of the covalent TPD field.
What are the application scenarios for this model?
Primary applications:
• CRL4-DCAF16 substrate identification: ubiquitinome analysis in DCAF16-null versus rescued cells to identify endogenous DCAF16 substrates.
• Covalent molecular glue specificity: critical genetic control for DCAF16-recruiting covalent molecular glue degraders — these compounds should have no degradation activity in DCAF16-null cells.
• Cysteine reactivity studies: rescue with cysteine-to-alanine mutants (C58A, C107A) for systematic characterization of cysteine-targeting covalent molecular glues.
• Targeted protein degradation platform: development of new DCAF16-recruiting molecular glue degraders and PROTACs.
EDITGENE recommends this model as a critical specificity tool for the rapidly emerging field of covalent molecular glue degraders targeting DCAF16.
Is this DCAF16 Knockout HeLa Cell Line compatible with overexpression rescue experiments?
Yes, and rescue experiments are uniquely powerful for covalent molecular glue research:
• Construct design: use a codon-modified DCAF16 sequence with a small C-terminal tag (FLAG, HA). DCAF16 contains the WD40-like substrate-receptor region with key surface cysteines (C58, C107, others) — preserve all elements.
• Cysteine-to-alanine rescue: C58A, C107A, and other cysteine mutations enable systematic characterization of which cysteines are required for covalent molecular glue recruitment — this is the gold-standard approach for understanding covalent ligand-DCAF16 mechanism.
• Functional readout: rescue should restore CRL4-DCAF16 complex assembly and substrate ubiquitination; covalent molecular glue degrader activity requires the specific cysteine being engaged.
HeLa transduces efficiently with lentivirus and supports systematic cysteine mutation analysis for the rapidly emerging covalent molecular glue degrader field.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.